资源类型:
期刊
收录情况:
◇ SCIE
文章类型:
论著
机构:
[1]Department of Anesthesiology, Xuanwu Hospital, Capital Medical University, Beijing 100053, PR China
麻醉手术科
[2]Department of Anesthesiology, The Second Affiliated Hospital of Soochow University, Suzhou 215004, PR China
ISSN:
1567-5769
关键词:
Acute lung injury
Acute respiratory distress syndrome
EphA2
Nrf2
RhoA
TLR4
摘要:
Eph receptor tyrosine kinases have a wide range of biological functions and have gradually been recognized increasingly as key regulators of inflammation and injury diseases. Although previous studies suggested that EphA2 receptor may be involved in the regulation of inflammation and vascular permeability in injured lung, the detailed effects of EphA2 on LPS-induced acute lung injury (ALI) are still inadequate and the underlying mechanism remains poorly understood. In this study, we detected the effects of EphA2 antagonism on inflammation, pulmonary vascular permeability and oxidative stress in LPS-induced ALI and investigate the potential mechanism. Our results showed that EphA2 antagonism markedly inhibited the cytokines release and inflammatory cells infiltration in BALF, prevented the LPS-induced elevations of MPO activity and MDA level in lung tissues. Our study also found that EphA2 antagonism significantly decreased the wet/dry ratios, reduced the Evans blue albumin extravasation in lung tissues and obviously alleviated the LPS-induced increment of pulmonary vascular permeability. Mechanistically, EphA2 antagonism significantly increased the activation of Nrf2 along with its target antioxidant enzyme HO-1 and inhibited the expressions of TLR4/MyD88 in lung tissues and A549 alveolar epithelial cells. Furthermore, EphA2 antagonism dramatically inhibited the LPS-evoked activations of RhoA/ROCK in lung tissues. In conclusion, our data indicate that EphA2 receptor plays an essential role in LPS-induced ALI and EphA2 antagonism has protective effects against LPS-induced ALI via Nrf2/HO-1, TLR4/MyD88 and RhoA/ROCK pathways. These results suggest that antagonism of EphA2 may be an effective therapeutic strategy for the treatment of ALI. © 2019 Elsevier B.V.
被引次数:
30
WOS:
WOS:000471087000020
PubmedID:
30986645
中科院(CAS)分区:
出版当年[2018]版:
大类
|
3 区
医学
小类
|
3 区
免疫学
3 区
药学
最新[2023]版:
大类
|
2 区
医学
小类
|
2 区
免疫学
2 区
药学
JCR分区:
出版当年[2017]版:
Q2
PHARMACOLOGY & PHARMACY
Q3
IMMUNOLOGY
最新[2023]版:
Q1
PHARMACOLOGY & PHARMACY
Q2
IMMUNOLOGY
影响因子:
4.8
最新[2023版]
5
最新五年平均
3.118
出版当年[2017版]
3.056
出版当年五年平均
2.956
出版前一年[2016版]
3.361
出版后一年[2018版]
第一作者:
Guang Feng
第一作者机构:
[1]Department of Anesthesiology, Xuanwu Hospital, Capital Medical University, Beijing 100053, PR China
通讯作者:
Tian-long Wang
通讯机构:
[1]Department of Anesthesiology, Xuanwu Hospital, Capital Medical University, Beijing 100053, PR China
推荐引用方式(GB/T 7714):
Guang Feng,Bo Sun,Hai-xia Liu,et al.EphA2 antagonism alleviates LPS-induced acute lung injury via Nrf2/HO-1, TLR4/MyD88 and RhoA/ROCK pathways[J].International Immunopharmacology.2019,72:176-185.doi:10.1016/j.intimp.2019.04.008.
APA:
Guang Feng,Bo Sun,Hai-xia Liu,Qing-hai Liu,Lei Zhao&Tian-long Wang.(2019).EphA2 antagonism alleviates LPS-induced acute lung injury via Nrf2/HO-1, TLR4/MyD88 and RhoA/ROCK pathways.International Immunopharmacology,72,
MLA:
Guang Feng,et al."EphA2 antagonism alleviates LPS-induced acute lung injury via Nrf2/HO-1, TLR4/MyD88 and RhoA/ROCK pathways".International Immunopharmacology 72.(2019):176-185